PDCD1 and melanoma: Current standard of care for clinically detectable, resectable stage III melanoma includes adjuvant anti-programmed cell death protein 1 (PD-1) therapy or BRAF-targeted therapy for patients treated with upfront resection, or neoadjuvant nivolumab plus ipilimumab followed by adjuvant therapy based on pathological response and BRAF status, or neoadjuvant plus adjuvant pembrolizumab1–5.